Organon & Co. (NYSE:OGN) is among the 7 Oversold Pharma Stocks to Buy Now. Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% Organon & Co. (NYSE:OGN) is among the most oversold pharma stocks. TheFly reported on February 12 that OGN announced its fourth-quarter and full-year 2025 financial results. According to the report, for the full year, the company’s revenue totaled $6.2 billion, which represents a 3% decline both on a reported basis and in constant currency. Diluted earning ...

Core Insights - Organon reported $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for 2025, with a 3% decline in revenue on both reported and ex-FX basis, although the biosimilar franchise performed better than expected, particularly driven by HADLIMA [2][3][4] Revenue and Financial Performance - The company guided for approximately $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for 2026, indicating a stable outlook compared to 2025 [3][20] - Adjusted gross margin is expected to decline by about 75–100 basis points in 2026, primarily due to higher cost of goods sold [21] - Organon reported a Q4 2025 net loss of $205 million, influenced by a $301 million goodwill impairment, while non-GAAP adjusted net income was $165 million for Q4 and $954 million for the full year [16][17] Biosimilars and Product Performance - The biosimilars segment, particularly HADLIMA, grew approximately 61% ex-FX in 2025, with expectations for flat to modest growth in 2026 [4][11][12] - The company launched a denosumab biosimilar in the U.S. in late September 2025, contributing to the biosimilars growth [11] - Nexplanon received FDA approval to extend its duration from three to five years, but management anticipates a volume headwind due to policy-driven access changes and a shift in reinsertions [5][9][10] Strategic Focus and Outlook - Organon aims to stabilize revenue, maintain profitability, and continue deleveraging, with a target of net leverage below 4.0x by the end of 2026 [3][18] - The company plans to reduce its dividend payout ratio to support debt reduction and has divested the JADA System, generating approximately $390 million in net proceeds [18][20] - Management expects interest expense of about $500 million and depreciation of about $140 million for 2026, with a non-GAAP tax rate projected between 27.5% and 29.5% [22]

Core Insights - The company experienced a 3% revenue decline in 2025 due to the loss of exclusivity for Atozet and challenges in the respiratory franchise, particularly from policy impacts on Singulair [1] Revenue Performance - The biosimilars franchise exceeded internal expectations, with Hadlima achieving a 61% growth and successful market expansion into Canada and Puerto Rico [1] Operational Efficiency - The company focused on operational efficiency, achieving over $200 million in cost savings, which helped maintain adjusted EBITDA margins despite a 150 basis points decline in gross margin [1] Strategic Initiatives - The divestiture of the Jada system for $390 million and a reduction in the dividend payout ratio indicate a strategic shift towards enhancing balance sheet capacity and reducing debt [1] - Management has discontinued early-stage clinical programs to concentrate on medical and regulatory support for existing products and high-potential growth drivers like Vtama [1] Regulatory Developments - The FDA's approval to extend Nexplanon's duration from 3 to 5 years is seen as a significant milestone to expand the addressable market, especially for overweight and obese patients [1] Strategic Positioning - The company aims to leverage its global infrastructure to integrate low-incremental-cost assets such as Emgality and Nilemdo, focusing on established brands [1]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Sun Pharmaceutical Industries Ltd. is talking with advisers about a possible bid for New York-listed wellness company Organon & Co., according to people familiar with the matter.India’s biggest pharmaceutical company, with a market capitalisation of $43 billion, has held preliminary discussions with global lenders to arrange financing for a possible deal, the people said, asking not to be identified because the information is private. Considerations are preliminary and Sun Pharma may decide to not pursue a ...

Group 1 - The National Bureau of Statistics predicts that by the end of 2025, the number of household cars in China will reach 52.9 vehicles per hundred households, driven by proactive macro policies aimed at economic structure optimization [2] - The "Dead or Alive" app team warns users about counterfeit applications that closely resemble their product, which mislead users and infringe on the company's intellectual property [3] - Merck China has signed a memorandum of cooperation with Megrey Chemical to develop customized AI models, enhancing molecular synthesis speed and shortening product development cycles [4] Group 2 - JD Technology has increased its registered capital from approximately 5.3 billion RMB to about 5.39 billion RMB, indicating growth in its business operations [5] - TSMC's stock price reached a new high of 1780 NTD, with a market capitalization exceeding 46 trillion NTD, benefiting from strong AI market demand and expected revenue growth [6] - The National Anti-Monopoly Bureau has launched its official accounts on WeChat, Weibo, and Douyin to promote fair competition and transparency in antitrust policies [7] Group 3 - In 2025, the national real estate market saw a total sales volume of 8.39 trillion RMB, with signs of recovery in first-tier cities as new home prices increased [8] - China Pacific Insurance expects a profit increase of approximately 215% to 225% in 2025 compared to 2024, driven by improved net investment performance and favorable tax policies [11] - Disney's "Zootopia 2" has become the highest-grossing animated film in Hollywood history, with a global box office of $1.703 billion [12]

Group 1 - The Chinese Council for the Promotion of International Trade organized a delegation of Chinese entrepreneurs to engage in discussions with the US-China Business Council and its member companies in Washington [1][3] - The President of the Chinese Council, Ren Hongbin, emphasized the long-standing cooperation between the Council and the US-China Business Council, highlighting their contributions to strengthening economic ties and promoting bilateral relations over the past fifty years [3] - Ren expressed a commitment to continue working with the US-China Business Council to uphold the important consensus reached during the recent summit between the two countries' leaders, aiming to foster greater collaboration and stability in global supply chains [3] Group 2 - US-China Business Council President, Tom Donohue, noted that the American business community remains a strong advocate for engagement and dialogue between the two nations [3] - The upcoming APEC meeting in 2026, which will be hosted by China, presents an opportunity for deeper cooperation between the US and China, with American companies eager to participate constructively [3] - Over 80 representatives from both American and Chinese companies, including FedEx, Thermo Fisher Scientific, PayPal, ExxonMobil, and others, attended the event, indicating strong interest in bilateral business relations [3]

上海寶濟藥業股份有限公司 Shanghai Bao Pharmaceuticals Co., Ltd. 股份代號 : 2659 （於中華人民共和國成立的股份有限公司） 全球發售 聯席保薦人、整體協調人、聯席全球協調人、 聯席賬簿管理人及聯席牽頭經辦人 重要提示 重要提示：倘 閣下對本招股章程的任何內容有任何疑問，應尋求專業獨立意見。 Shanghai Bao Pharmaceuticals Co., Ltd. 上海寶濟藥業股份有限公司 （於中華人民共和國成立的股份有限公司） 全球發售 香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本招股章程的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明 確表示，概不就因本招股章程全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本招股章程副本連同附錄八「送呈香港公司註冊處處長及展示文件」所列的文件已遵照香港法例第32章公司（清盤及雜項條文）條例第342C條的規定送呈香港公 司註冊處處長登記。證券及期貨事務監察委員會及香港公司註冊處處長對本招股章程或上述任何其他文件的內容概不負責。 發售價將為每股發售股份26.38港元。 ...

Core Insights - Alibaba Health reported a revenue of RMB 16.697 billion for the six months ending September 30, 2025, representing a year-on-year growth of 17% [1] - The company achieved a net profit of RMB 1.266 billion, marking a significant increase of 64.7% compared to the previous year [1] - Alibaba Health continues to invest in the medical AI sector and deepen its strategic layout in the B2B medical verticals [1] Financial Performance - Revenue reached RMB 16.697 billion, up 17% year-on-year [1] - Gross profit was RMB 4.184 billion, reflecting an 18.4% increase [1] - Adjusted net profit stood at RMB 1.356 billion, a growth of 38.7% [1] User Engagement and Platform Growth - The Tmall Health platform serves over 56,000 merchants, with SKU growth exceeding 97 million [1] - Annual active user numbers and annualized ARPU continue to grow, with platform GMV showing stable growth [1] - The self-operated pharmacy business generated revenue of RMB 14.38 billion, up 18.6% year-on-year [1] Strategic Partnerships and Service Expansion - Alibaba Health has deepened collaborations with major pharmaceutical companies, launching dozens of new specialty drugs [2] - Strategic partnerships with companies like Eli Lilly, AstraZeneca, and Pfizer have been established to enhance digital health services [2] - The company provides integrated online and offline healthcare services, with over 250,000 healthcare professionals signed up for online consultation services [2] Traditional Chinese Medicine and Digital Infrastructure - The TCM service business is experiencing stable growth, with over 150,000 registered TCM practitioners [3] - The "Code on Trust" platform offers free traceability services to 560,000 pharmaceutical enterprises [3] - Alibaba Health is enhancing its digital services for pharmaceutical companies, collaborating with over 900 leading pharmaceutical firms [3] AI and Future Prospects - The company is increasing resource investment in medical AI applications to improve user experience and search conversion efficiency [3] - Alibaba Health is exploring applications in serious medical fields to enhance evidence-based capabilities in clinical decision-making [3]

Core Viewpoint - Alibaba Health reported strong financial performance for the first half of the 2026 fiscal year, with revenue reaching RMB 16.697 billion, a year-on-year increase of 17%, and net profit growing by 64.7% to RMB 1.266 billion, indicating robust business growth and high-quality development [1] Financial Performance - Revenue for the six months ending September 30, 2025, was RMB 16.697 billion, up 17% year-on-year [1] - Gross profit reached RMB 4.184 billion, reflecting an 18.4% increase [1] - Net profit was RMB 1.266 billion, a significant rise of 64.7% [1] - Adjusted net profit stood at RMB 1.356 billion, marking a 38.7% year-on-year growth [1] Business Growth and User Engagement - Alibaba Health is one of the largest online B2C healthcare product retail platforms in China, with over 56,000 active merchants and more than 97 million SKUs [2] - The platform's annual active user count and ARPU (average revenue per user) continue to grow, with GMV (gross merchandise volume) showing stable year-on-year growth [2] - The self-operated pharmacy business generated RMB 14.38 billion in revenue, up 18.6% year-on-year, with a significant increase in active users and SKU growth of 98.8% to 1.61 million [2] Strategic Partnerships and Service Expansion - Alibaba Health has formed strategic partnerships with major pharmaceutical companies like Eli Lilly, AstraZeneca, and Bayer to enhance digital health services and expand market reach [3] - The company provides integrated online and offline healthcare services, with over 250,000 healthcare professionals offering online consultation services [3] - The self-operated chronic disease business has seen continuous growth in user numbers and ARPU [3] Digital Infrastructure and AI Development - The "Code on Trust" platform offers free traceability services to 56,000 pharmaceutical terminal enterprises, expanding into medical devices and traditional Chinese medicine [4] - Alibaba Health collaborates with over 900 leading pharmaceutical companies to provide data analysis services [4] - The company is investing in AI applications within the pharmaceutical e-commerce sector to enhance user experience and search conversion efficiency, while also exploring applications in serious medical fields [4]